News

Press Release | 16 December 2011

SEATTLE — Integrated Diagnostics announced today that researchers from the company and the California Institute of Technology (Caltech) will receive a Point-of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines — including those who have not traditionally taken part in health research — to work on solutions that could lead to breakthrough advances for those in the developing world. Jim Heath, Ph.D., co-founder and Board member, Integrated Diagnostics; Gilloon Professor, Caltech will pursue an innovative point-of-care diagnostics project, titled Protein Capture Agents with 40 oC shelf life for developing world point-of-care HIV-1 diagnostics.

Press Release | 26 October 2011

Protein-Catalyzed Capture Agents (PCCs) Designed Using “Click Chemistry” Show Promise for Broad Use in Diagnostics and Therapeutics

Data Demonstrating Synthetic Class of Site-Specific Binding Molecules is Published in the Journal of the American Chemical Society

SEATTLE — Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has created a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology (Caltech) using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with unusual precision and stability. PCCs offer the promise of superior stability, lower cost and faster creation compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses. Data demonstrating the design and use of this synthetic class of site-specific binding molecules was recently published in the Journal of the American Chemical Society (JACS). In a separate release, Integrated Diagnostics also announced that it has licensed click chemistry from The Scripps Research Institute and appointed K. Barry Sharpless, Ph.D., the inventor of the process, as an advisor.

Press Release | 26 October 2011
Dr. Barry Sharpless, Nobel Laureate and Click Chemistry Pioneer, Joins Integrated Diagnostics as Advisor

SEATTLE — Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has signed a worldwide licensing agreement with The Scripps Research Institute, strengthening its growing network of partners. Under the license, the company will have access to “click chemistry,” a powerful chemical process developed by K. Barry Sharpless, Ph.D. Integrated Diagnostics concurrently announced that it has appointed Dr. Sharpless, who shared in the 2001 Nobel Prize for Chemistry, as an advisor. In a separate release, the company announced that it has used click chemistry in collaboration with the California Institute of Technology (Caltech) to create a synthetic class of diagnostic and therapeutic agents, with antibody-like properties.